Kiki Patel
Head of Investor Relations
Replay available
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call
Vir Biotechnology, Inc. (NASDAQ: VIR) Q4 2025 earnings conference call, held 2026-02-23. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Marianne DeBoffer
Chief Executive Officer
Dr. Mark Eisner
Chief Medical Officer
Dr. Johan de Bono
Clinical Investigator, Institute of Cancer Research
Jason O'Byrne
Chief Financial Officer
Paul Choi
Analyst, Goldman Sachs
Josh Sauron
Analyst, Evercore ISI
Ronna Ruiz
Analyst, Leerink Partners
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Vir Biotechnology, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.316 Good afternoon and welcome to Veer Biotechnology's conference call to discuss the company's 00:00:04.316 -- 00:00:09.482 Veer 5500 strategic collaboration with Astellas in positive phase one data and 2025 00:00:09.482 -- 00:00:14.408 financial results. As a reminder, this conference call is being recorded. 00:00:14.408 -- 00:00:17.312 At this time, all participants are in a listen-only mode. 00:00:17.312 -- 00:00:21.537 After the speaker's presentation, there will be a question and answer session. 00:00:21.537 -- 00:00:24.981 I will now turn the call over to Kiki Patel, head of investor relations. 00:00:24.981 -- 00:00:27.522 You may begin, Kiki. 00:00:28.065 -- 00:00:30.608 Thank you, operator, and welcome, everyone. 00:00:30.608 -- 00:00:35.338 Earlier today, we issued three press releases, including a joint release with Astellas 00:00:35.338 -- 00:00:40.369 announcing a strategic collaboration with our PSMA-directed T-cell engager, VIR 00:00:40.369 -- 00:00:41.832 5500. 00:00:41.832 -- 00:00:47.584 A second release reporting the Phase 1 VIR 5500 data that will be presented at ASCO GU, 00:00:47.584 -- 00:00:52.327 and a third release reporting our fourth quarter and year-end earnings. 00:00:52.327 -- 00:00:56.434 Before we begin, I would like to remind everyone that some of the statements we are making 00:00:56.434 -- 00:01:00.461 today are forward-looking statements under applicable securities laws. 00:01:00.461 -- 00:01:04.448 These forward-looking statements involve substantial risks and uncertainties that could 00:01:04.448 -- 00:01:09.918 cause our clinical development programs, collaboration outcomes, future results, performance, 00:01:09.918 -- 00:01:14.626 or achievements to differ significantly from those expressed or im...